Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05300438 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

A Phase 1 study of Cancer (With or Without Metastasis), sponsored by Tyligand Bioscience (Shanghai) Limited.

Active
Registry status
Phase 1
Development phase
74
Enrollment target
1
Study location

NCT05300438 is a Phase 1 study of Cancer (With or Without Metastasis) that is active but no longer recruiting, run by Tyligand Bioscience (Shanghai) Limited. The registered enrollment target is 74 participants, below the 450-participant average among 3 other Cancer (With or Without Metastasis) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05300438, a Phase 1 study of Cancer (With or Without Metastasis), is active but no longer recruiting, sponsored by Tyligand Bioscience (Shanghai) Limited.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.

Interventions

  • DRUG TSN084

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2022-02-18
Est. Completion 2025-06
Phase Phase 1

What the Registry Record Tells You About NCT05300438

The ClinicalTrials.gov registry entry for NCT05300438 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 450-participant average among 3 other Cancer (With or Without Metastasis) trials with a reported enrollment target (84% lower). The listed sponsor is Tyligand Bioscience (Shanghai) Limited, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer (With or Without Metastasis) appearing as the primary indexed condition, and to 1 intervention - of which TSN084 is the first listed.

NCT05300438 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05300438 about?

NCT05300438 is a clinical study titled "Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.". TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose...

What is the current status of trial NCT05300438?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-02-18. Estimated completion is 2025-06.

What conditions does trial NCT05300438 study?

This clinical trial studies the following conditions: Cancer (With or Without Metastasis).

What interventions are being tested in trial NCT05300438?

The interventions under investigation include: TSN084 (DRUG).

Who is sponsoring clinical trial NCT05300438?

This trial is sponsored by Tyligand Bioscience (Shanghai) Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05300438 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer (With or Without Metastasis)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.